<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02571036</url>
  </required_header>
  <id_info>
    <org_study_id>DCC-2618-01-001</org_study_id>
    <nct_id>NCT02571036</nct_id>
  </id_info>
  <brief_title>A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies</brief_title>
  <official_title>A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deciphera Pharmaceuticals LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Deciphera Pharmaceuticals LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, open-label, first-in-human (FIH) dose-escalation study designed to&#xD;
      evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and&#xD;
      preliminary antitumor activity of DCC-2618, administered orally (PO), in adult patients with&#xD;
      advanced malignancies. The study consists of 2 parts, a dose-escalation phase, and an&#xD;
      expansion phase. All active patients (from both dose-escalation and expansion phases) will&#xD;
      then transition into an extension phase.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety/tolerability of oral DCC-2618: incidence of adverse events</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Dose limiting toxicities, AEs, SAEs, discontinuation of drug due to toxicity, physical exams and ECOG PS, ophthalmologic examinations, changes from baseline in laboratory parameters, electrocardiograms, LVEF, and vital signs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of the Maximum Tolerated Dose and the Recommended Phase 2 Dose</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Expansion Phase: Assess Antitumor Activity of DCC-2618 in all diseases</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Objective response rate (ORR); Disease control rate (DCR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the PK profile of oral DCC-2618</measure>
    <time_frame>Predose and up to 24 hours postdose (Cycle = 28 Days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Escalation Phase: Assess Antitumor Activity of DCC-2618 in patients with advanced malignancies</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Objective response rate (ORR); Disease control rate (DCR)</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Gastrointestinal Stromal Tumors</condition>
  <condition>Advanced Systemic Mastocytosis</condition>
  <condition>Advanced Cancers</condition>
  <arm_group>
    <arm_group_label>Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalation Phase: DCC-2618 tablets in escalating dose cohorts given orally BID (twice daily) every 12 hours or once daily (QD) for repeated 28-day cycles. Participants may continue to receive study drug until discontinuation criteria are met. [Closed for Enrollment]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with GIST who have received 3 prior therapies. [Closed for Enrollment]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with GIST who have received 4 prior therapies. [Closed for Enrollment]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with GIST who have received at least one prior therapy and no more than 2 prior therapies. [Closed for Enrollment]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with systemic mastocytosis and other hematologic malignancies.[Closed for Enrollment]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with malignant gliomas.[Closed for Enrollment]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with other solid tumors. [Closed for Enrollment]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Cohort 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with melanomas. [Closed for Enrollment]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Cohort 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with soft tissue sarcomas.[Closed for Enrollment]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Cohort 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with germ cell, penile cancer and non-small cell lung carcinoma (NSCLC). [Closed for Enrollment]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Cohort 10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with GIST and other solid tumors with renal impairment. [Closed for Enrollment]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Extension Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg DCC-2618 given once daily in repeated 28-day cycles for active patients from the Escalation and Extension Phases.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DCC-2618</intervention_name>
    <description>50 mg formulated tablets</description>
    <arm_group_label>Expansion Cohort 1</arm_group_label>
    <arm_group_label>Expansion Cohort 10</arm_group_label>
    <arm_group_label>Expansion Cohort 2</arm_group_label>
    <arm_group_label>Expansion Cohort 3</arm_group_label>
    <arm_group_label>Expansion Cohort 4</arm_group_label>
    <arm_group_label>Expansion Cohort 5</arm_group_label>
    <arm_group_label>Expansion Cohort 6</arm_group_label>
    <arm_group_label>Expansion Cohort 7</arm_group_label>
    <arm_group_label>Expansion Cohort 8</arm_group_label>
    <arm_group_label>Expansion Cohort 9</arm_group_label>
    <arm_group_label>Extension Cohort</arm_group_label>
    <other_name>ripretinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DCC-2618</intervention_name>
    <description>10 mg and 50 mg formulated tablets</description>
    <arm_group_label>Escalation</arm_group_label>
    <other_name>ripretinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (Escalation and Expansion Phases)&#xD;
&#xD;
        Patients must meet the following criteria to be eligible to enroll in the study:&#xD;
&#xD;
          1. Male or female patients â‰¥18 years of age.&#xD;
&#xD;
          2. Patients must have histologically confirmed solid tumors or hematologic malignancies.&#xD;
             Eligible patients include the following:&#xD;
&#xD;
               1. GIST patients must have a KIT and PDGFRA mutation and must have progressed on or&#xD;
                  had an intolerability to at least 1 line of systemic anticancer therapy.&#xD;
&#xD;
               2. SM patients must have a confirmed diagnosis of advanced SM according to 2016&#xD;
                  World Health Organization (WHO) criteria for SM and must have documented KIT&#xD;
                  mutant disease. Patients with imatinib-sensitive KIT mutations must have&#xD;
                  progressed on or were intolerant to a tyrosine kinase inhibitor. Patients with&#xD;
                  advanced SM must present with at least 1 eligible C-Finding (organ damage) per&#xD;
                  2013 International Working Group-Myeloproliferative Neoplasms Research and&#xD;
                  Treatment (IWG-MRT) &amp; European Competence Network on Mastocytosis consensus&#xD;
                  response criteria; please see below for MCL exception.&#xD;
&#xD;
             Advanced SM includes:&#xD;
&#xD;
             i. Aggressive SM (ASM)&#xD;
&#xD;
             ii. SM with associated hematologic neoplasm (SM-AHN), wherein the AHN does not require&#xD;
             immediate alternative therapy. AHNs that are eligible include: low grade&#xD;
             myelodysplastic syndrome (MDS) with a high SM burden who require treatment for SM&#xD;
             only, myeloproliferative neoplasms (MPN), MDS/MPN, unclassifiable MDS, and HES/CEL.&#xD;
&#xD;
             iii. MCL&#xD;
&#xD;
             â€¢ Patients with histopathologically-confirmed MCL without a C-finding are eligible.&#xD;
&#xD;
             iv. Symptomatic SSM&#xD;
&#xD;
             â€¢ By definition, SSM patients must have at least 2 B-findings, and clinically&#xD;
             significant symptom burden (eg, flushing, diarrhea, etc.) despite maximal treatment&#xD;
             with approved agents to treat mediator symptoms, such as antihistamines and cromolyn&#xD;
             sodium.&#xD;
&#xD;
             v. Patients with hematologic malignancies featuring clonal expansion of eosinophils&#xD;
             driven by genomic alterations of KIT or PDGFRA (eg, HES or CEL) are eligible if they&#xD;
             have progressed on or are intolerant of imatinib therapy. Patients with de novo&#xD;
             imatinib resistant mutations, such as but not limited to KIT D816V or PDGFRA D842V,&#xD;
             are eligible without prior imatinib therapy.&#xD;
&#xD;
             c. Malignant glioma patients with genomic alterations potentially conferring&#xD;
             sensitivity to DCC-2618 including, but not limited to, amplification and/or mutations&#xD;
             of PDGFRA and/or KIT.&#xD;
&#xD;
             Other solid tumor patients that have alterations in genes encoding kinases that are&#xD;
             targets of DCC-2618. This includes:&#xD;
&#xD;
               -  Melanoma&#xD;
&#xD;
               -  Soft tissue sarcoma patients (including but not limited to: malignant peripheral&#xD;
                  nerve sheath tumors (MPNST), desmoplastic small round cell tumors (DSRCT), and&#xD;
                  dermatofibrosarcoma protuberans tumors (DFSP)&#xD;
&#xD;
               -  Other solid tumor patients (non-melanoma, non-STS; specifically germ-cell,&#xD;
                  penile, and non-small cell lung carcinoma)&#xD;
&#xD;
               -  Renal impairment cohort&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of â‰¤2.&#xD;
&#xD;
          4. Adequate organ function and bone marrow function.&#xD;
&#xD;
        Exclusion Criteria (Escalation and Expansion Phases)&#xD;
&#xD;
        Patients meeting any of the following criteria will be excluded from the study:&#xD;
&#xD;
          1. GIST patients with wild type or unknown KIT or PDGFRA status.&#xD;
&#xD;
          2. Patients with SM or other hematologic malignancies will be excluded if the following&#xD;
             apply:&#xD;
&#xD;
               1. SM patients with neutropenia accompanied by fever or infection, or&#xD;
                  thrombocytopenia associated with clinically significant bleeding.&#xD;
&#xD;
                  â€¢ Patients with an infection that is well controlled with antibiotics are&#xD;
                  eligible if there is an immediate need for treatment.&#xD;
&#xD;
               2. SM-AHN patients diagnosed with:&#xD;
&#xD;
             i. SM with MDS who require treatment for MDS. ii. Patients requiring immediate&#xD;
             treatment for AHN.&#xD;
&#xD;
             c. Patients with leukemias, with the exception of MCL and CEL, that have progressed&#xD;
             after imatinib.&#xD;
&#xD;
             d. Eosinophilic myeloproliferative neoplasm patients: i. Lacking a mutation that is a&#xD;
             known target of DCC-2618.&#xD;
&#xD;
          3. Prior or concurrent malignancy whose natural history or treatment have the potential&#xD;
             to interfere with the safety or efficacy assessment of DCC-2618. Patients receiving&#xD;
             adjuvant cancer treatment are not eligible if those medications are potentially active&#xD;
             against GIST or excluded per protocol.&#xD;
&#xD;
          4. New York Heart Association class III and IV heart disease, active ischemia or any&#xD;
             other uncontrolled cardiac condition such as angina pectoris, clinically significant&#xD;
             cardiac arrhythmia requiring therapy, uncontrolled hypertension or congestive heart&#xD;
             failure.&#xD;
&#xD;
          5. Arterial thrombotic or embolic events such as cerebrovascular accident (including&#xD;
             ischemic attacks) or hemoptysis within 6 months before start of study drug.&#xD;
&#xD;
          6. Venous thrombotic events (eg, deep vein thrombosis) or pulmonary arterial events (eg,&#xD;
             pulmonary embolism) within the 3 months before start of study drug. Patients with&#xD;
             venous thrombotic events â‰¥3 months before start of study drug on stable&#xD;
             anticoagulation therapy are eligible.&#xD;
&#xD;
          7. Baseline prolongation of the rate-corrected QT interval based on repeated&#xD;
             demonstration of QT interval corrected by Fridericia's formula (QTcF) &gt;450 ms in males&#xD;
             or &gt;470 ms in females or history of long QT interval corrected (QTc) syndrome.&#xD;
&#xD;
          8. Left ventricular ejection fraction (LVEF) &lt;50% or below the lower limit of normal&#xD;
             (whichever is higher).&#xD;
&#xD;
          9. Major surgery within 4 weeks of the first dose of study drug; following major&#xD;
             surgeries &gt;4 weeks prior to the first dose of study drug, all surgical wounds must be&#xD;
             healed and free of infection or dehiscence.&#xD;
&#xD;
         10. Any other clinically significant comorbidities.&#xD;
&#xD;
         11. Illnesses that could affect oral absorption.&#xD;
&#xD;
         12. Known human immunodeficiency virus or active hepatitis C infection only if the patient&#xD;
             is taking per protocol prohibited medications, active hepatitis B, or active hepatitis&#xD;
             C infection.&#xD;
&#xD;
         13. If female, the patient is pregnant or lactating.&#xD;
&#xD;
         14. Known allergy or hypersensitivity to any component of the investigational drug&#xD;
             product. Patients with history of Stevens-Johnson syndrome on a prior tyrosine kinase&#xD;
             inhibitor (TKI) are excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deciphera Pharmaceuticals, LLC</last_name>
    <role>Study Director</role>
    <affiliation>Deciphera Pharmaceuticals LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Honor Health (GIST, mastocytosis, other solid tumors)</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Hematology Center (mastocytosis)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA (glial malignancies only)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Comprehensive Cancer Center (GIST)</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Hematology Clinic (mastocytosis)</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF (glial malignancies only)</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic (GIST, mastocytosis, glial malignancies, other solid tumors)</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami (GIST, mastocytosis, glial malignancies, other solid tumors)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute (GIST, mastocytosis, glial malignancies, other solid tumors)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colombia University Medical Center (mastocytosis)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center (GIST, mastocytosis, glial malignancies, other solid tumors)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OHSU (GIST &amp; mastocytosis only)</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center (GIST only)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center (GIST, mastocytosis, glial malignancies, other solid tumors)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute (GIST, mastocytosis, glial malignancies, other solid tumors)</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University School of Medicine (mastocytosis)</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre (GIST, other solid tumors)</name>
      <address>
        <city>Toronto</city>
        <zip>M5G IX5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik RWTH Aachen (mastocytosis, GIST, and other solid tumors)</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Berlin-Buch (GIST, and other solid tumors)</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Essen University Hospital (mastocytosis, GIST, and other solid tumors)</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Freiburg University Hospital (mastocytosis, and other solid tumors)</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Centre Mannheim (mastocytosis)</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Verona (mastocytosis)</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center (GIST and other solid tumors)</name>
      <address>
        <city>Leiden</city>
        <zip>2333</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's Hospital (mastocytosis only)</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital (GIST, glial malignancies, other solid tumors)</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
    <country>Spain</country>
  </removed_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 5, 2015</study_first_submitted>
  <study_first_submitted_qc>October 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2015</study_first_posted>
  <last_update_submitted>April 16, 2021</last_update_submitted>
  <last_update_submitted_qc>April 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastrointestinal stromal tumors (GIST)</keyword>
  <keyword>systemic mastocytosis (SM)</keyword>
  <keyword>PDGFR-alpha</keyword>
  <keyword>KIT</keyword>
  <keyword>mast cell leukemia (MCL)</keyword>
  <keyword>mast cell disease (MCD)</keyword>
  <keyword>DCC-2618</keyword>
  <keyword>melanoma</keyword>
  <keyword>aggressive systemic mastocytosis (ASM)</keyword>
  <keyword>soft tissue sarcoma (STS)</keyword>
  <keyword>germ cell tumors</keyword>
  <keyword>penile cancer</keyword>
  <keyword>non-small cell lung carcinoma (NSCLC)</keyword>
  <keyword>renal impairment</keyword>
  <keyword>malignant gliomas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
    <mesh_term>Mastocytosis</mesh_term>
    <mesh_term>Mastocytosis, Systemic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

